A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

Inclusion Criteria: * (1) Age ≥ 18 years old, with no gender restrictions. * (2) Disease progressed after receiving at least one anti-angiogenic and/or immune checkpoint inhibitor (including PD-1, PD-L1, CTLA-4) therapy, or the treatment is not tolerable. * (3) Histologically confirmed primary HCC with FGF19 overexpression, which meets the Barcelona Clinic Liver Cancer (BCLC) staging criteria for patients with stage B suitable for systemic therapy or stage C. * (4) At least one measurable lesion as defined by RECIST v1.1. * (5) Eastern Cooperative Oncology Group (ECOG) score ≤1. * (6) Expected survival ≥ 3 months. * (7) Adequate organ function. * (8) Female subjects of childbearing potential must have a negative pregnancy test prior to the first dose and are required to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. * (9) Fully informed of the study and voluntarily signed the informed consent form (ICF), and willing to follow and have the ability to complete all trial procedures. Exclusion Criteria: * (1) Use of systemic immunosuppressive or systemic cortisol (≥10 mg prednisone or other equivalent hormones) within 2 weeks. * (2) Prior use of selective FGFR4 inhibitor therapy. * (3) Use of Tyrosine kinase inhibitor within 2 weeks. * (4) Use of systemic chemotherapy, radiotherapy (\>30% bone marrow exposure), interventional embolization, ablation therapy and immunotherapycytotoxic chemotherapeutics within 4 weeks. * (5…